EUVIMEDEUVIMED entdecken
Open Access

Real-World Treatment Patterns and Clinical Outcomes After Platinum-Doublet Chemotherapy and Immunotherapy in Metastatic Non–Small Cell Lung Cancer: A Multiregional Chart Review in the United States, Europe, and Japan

Ticiana A Leal iD, Anandaroop Dasgupta, Dominick Latremouille-Viau iD, Carmine Rossi iD, Pragya Rai iD, Fabrice Barlesi, Stephen V Liu iD

JCO Global Oncology · 2024-03 · (10)

DOI: 10.1200/go.23.00483 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Global Oncology, 2024-03. Verfasst von Ticiana A Leal und 6 weiteren Autor:innen. Beteiligte Einrichtung: Winship Cancer Institute, Emory University, Atlanta, GA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE To characterize treatment patterns and real-world clinical outcomes of patients with metastatic non–small cell lung cancer (mNSCLC) who developed progression on an anti–PD-1/anti–PD-L1, herein referred to as anti–PD-(L)1, and platinum-doublet chemotherapy. METHODS Eligible oncologists/pulmonologists in the United States, Europe (France, Germany, and United Kingdom), and Japan completed electronic case report forms for patients with mNSCLC (no evidence of EGFR/ALK/ROS1 alterations). Eligible patients had disease progression on/after an anti–PD-(L)1 and platinum-doublet chemotherapy (received concurrently or sequentially), initiated a subsequent line of therapy (LOT) between 2017 and 2021, and had an Eastern Cooperative Oncology Group (ECOG) performance status 0-2 at this subsequent LOT initiation (index date). Overall survival (OS), time to treatment discontinuation (TTD), and real-world progression-free survival (rwPFS) after index were assessed using Kaplan-Meier analysis. RESULTS Overall, 160 physicians (academic, 54.4%; community, 45.6%) provided deidentified data from 487 patient charts (United States, 141; Europe, 218; Japan, 128; at mNSCLC diagnosis: median age 66 years, 64.7% male, 81.3% nonsquamous, 86.2% de novo mNSCLC; at line of interest initiation: 86.0% ECOG 0-1, 39.6% liver metastases, 18.9% brain metastases, 79.1% smoking history). The most common treatment regimens upon progression after anti–PD-(L)1/platinum-doublet chemotherapy were nonplatinum chemotherapy (50.5%), nonplatinum chemotherapy plus vascular endothelial growth factor receptor inhibitor (12.9%), and platinum-doublet chemotherapy (6.6%). Median OS was 8.8 months (squamous, 7.8 months; nonsquamous, 9.5 months). Median TTD was 4.3 months (squamous, 4.1 months; nonsquamous, 4.3 months). Median rwPFS was 5.1 months (squamous, 4.6 months; nonsquamous, 5.4 months). CONCLUSION In this multiregional, real-world analysis of pooled patient chart data, patients with mNSCLC who had disease progression after anti–PD-(L)1/platinum-doublet chemotherapy had poor clinical outcomes with various treatment regimens, demonstrating an unmet clinical need for effective options after failure on anti–PD-(L)1 and platinum-doublet chemotherapy treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsCarcinoma, Squamous CellHumansMaleUnited StatesAgedFemalePlatinumJapanProtein-Tyrosine KinasesVascular Endothelial Growth Factor AAntineoplastic Combined Chemotherapy ProtocolsProto-Oncogene ProteinsImmunotherapyDisease Progression

Substanzen

PlatinumProtein-Tyrosine KinasesVascular Endothelial Growth Factor AProto-Oncogene Proteins

Autor:innen und Institutionen

  • Winship Cancer Institute, Emory University, Atlanta, GA.
  • Eisai Inc, Nutley, NJ.
  • Analysis Group, Inc, Montréal, QC, Canada.
  • Merck & Co., Inc, Rahway, NJ.
  • Paris Saclay University & Gustave Roussy Institute, Paris, France.
  • Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.

ORCID-Profile: Ticiana A Leal, Dominick Latremouille-Viau, Carmine Rossi, Pragya Rai, Stephen V Liu

Zitieren

APA

Leal, T. A., Dasgupta, A., Latremouille-Viau, D., Rossi, C., Rai, P., Barlesi, F., & Liu, S. V. (2024). Real-World Treatment Patterns and Clinical Outcomes After Platinum-Doublet Chemotherapy and Immunotherapy in Metastatic Non–Small Cell Lung Cancer: A Multiregional Chart Review in the United States, Europe, and Japan. JCO Global Oncology. https://doi.org/10.1200/go.23.00483

Vancouver

Leal TA, Dasgupta A, Latremouille-Viau D, Rossi C, Rai P, Barlesi F, et al. Real-World Treatment Patterns and Clinical Outcomes After Platinum-Doublet Chemotherapy and Immunotherapy in Metastatic Non–Small Cell Lung Cancer: A Multiregional Chart Review in the United States, Europe, and Japan. JCO Global Oncology. 2024. doi:10.1200/go.23.00483

BibTeX
@article{Leal2024,
  author = {Leal, Ticiana A and Dasgupta, Anandaroop and Latremouille-Viau, Dominick and Rossi, Carmine and Rai, Pragya and Barlesi, Fabrice and Liu, Stephen V},
  title = {Real-World Treatment Patterns and Clinical Outcomes After Platinum-Doublet Chemotherapy and Immunotherapy in Metastatic Non–Small Cell Lung Cancer: A Multiregional Chart Review in the United States, Europe, and Japan},
  journal = {JCO Global Oncology},
  year = {2024},
  number = {10},
  doi = {10.1200/go.23.00483}
}
Kostenlos starten →